KRASG12C inhibitor JNJ-74699157
Term · Oncology and biomedicine · MLC-T-ONC-014678
An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
| Identifier | MLC-T-ONC-014678 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | G12C mutant KRAS protein inhibitor JNJ-74699157 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014678",
"term": "KRASG12C inhibitor JNJ-74699157",
"field": "Oncology and biomedicine",
"definition": "An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.",
"synonyms": [
"G12C mutant KRAS protein inhibitor JNJ-74699157"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/krasg12c-inhibitor-jnj-74699157/"
}
Record 9,832 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.